US OptionsDetailed Quotes

LFCR250117C2500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Dec 23 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

Comments

    $Lifecore Biomedical (LFCR.US)$
    Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
    Thursday, 19th December at 7:00 am
    Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
    Lifecore to Leverage Differentiated Capabilities and Knowledge in Fill and Finish to Support Nirsum's NIH-Funded NRS-033 Development Program
    CHASK...
    $Lifecore Biomedical (LFCR.US)$
    Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
    Lifecore Biomedical has announced an amendment and extension of its asset-based lending revolving credit facility with BMO. The amendment extends the facility term by three years to November 2027, simplifies and reduces interest rates, and provides greater flexibility regarding covenants and reporting requirements. This follows the company's recent $24.3 million private placement financ...
    $Lifecore Biomedical (LFCR.US)$ Press Release: Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock
    Dow Jones· 1 min ago
    $Lifecore Biomedical (LFCR.US)$
    Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
    Lifecore Biomedical (NASDAQ: LFCR) reported its fiscal year 2024 results, showing strong revenue growth of 24.2% to $128.3 million.
    The company's CDMO business grew 27%, while its HA raw material manufacturing increased 18%.
    Gross profit rose 49.5% to $41.9 million, with margin expanding to 32.6%.
    Key highlights include:
    Net income from con...
    The Justice Department's decision could boost the practice of self-reporting in cases of corporate misconduct, given Lifecore's amicable resolution. This change is essentially incentivizing transparency and cooperation amongst corporations during bribery investigations.
Read more